References
- Simonneau G, Galie N, Rubin L J, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43(12 Suppl S)5S–12S
- Gupta R, Perumandla S, Patsiornik Y, Niranjan S, Ohri A. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. J Natl Med Assoc 2006; 98: 1779–1782
- Alintas A, Karahan Z, Pasa S, Cil T, Boyraz T, Iltimur K, et al. Pulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis. Leuk Lymphoma 2007; 48: 1981–1987
- Farber H W, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655–1665
- Archer S L, Michelakis E D. An evidence-based approach to the management of pulmonary arterial hypertension. Curr Opin Cardiol 2006; 21: 385–392
- Badesch D B, Abman S H, Simonneau G, Rubin L J, McLaughlin V V. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917–1928
- Rich S, Kaufmann E. High dose titration of calcium channel blocking agents for idiopathic pulmonary hypertension: guidelines for short-term drug testing. J Am Coll Cardiol 1991; 18: 1323–1327
- Sitbon O, Humbert M, Jais X, Ioos V, Hamid A M, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105–3111
- Rubin L J, Badesch D B. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med 2005; 143: 282–292